Top Story

FDA grants priority review to Blinctyo to treat pediatric B-cell precursor ALL

May 4, 2016

The FDA granted priority review to blinatumomab for the treatment of pediatric and adolescent patients with Philadelphia chromosomenegative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Blinatumomab (Blincyto, Amgen) is approved in the United States for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL, based on data in adults.

In the Journals

Chemoradiotherapy does not prolong OS in locally advanced pancreatic cancer

May 4, 2016
The addition of radiation to chemotherapy failed to improve OS for patients with locally advanced pancreatic cancer, according to the results of the randomized…
In the Journals

Zoledronic acid reduces skeletal complications for men with progressive bony prostate cancer

May 3, 2016
The addition of zoledronic acid to docetaxel significantly reduced the rate of skeletal-related events but did not prolong OS or clinical PFS among men with metastatic…
Meeting News CoverageVideo

VIDEO: Copper depletion affects tumor microenvironment in patients at high risk for breast cancer recurrence

May 3, 2016
NEW ORLEANS — Linda T. Vahdat, MD, MBA, medical oncologist and director of the breast cancer research program at Weill Cornell Medicine and NewYork-Presbyterian…

AMA, ACP applaud CMS Medicare proposals

May 3, 2016
The AMA and the American College of Physicians have announced their support of a proposal to modernize Medicare payments.CMS issued the proposal as a first step in…
More News Headlines »

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Meeting News Coverage

VIDEO: CAR-T cell therapy may target EGFR variant III in glioblastoma

April 26, 2016
More »
CME Video

World Lung Updates: Immunotherapy in NSCLC

This activity is supported by an educational grant from Genentech, Inc and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
Current Issues
View the Current Issue
HemOnc Today